SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Board appointment

12 Nov 2015 07:00

RNS Number : 4321F
Silence Therapeutics PLC
12 November 2015
 



 

 

 

Board appointment

12th November 2015

 

Silence Therapeutics plc

 

 

Silence Therapeutics plc, AIM: SLN ('Silence' or 'the Company'), a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, is pleased to announced the appointment of Alistair Gray as Non-Executive Director of the Company, with immediate effect. Alistair will also Chair the Audit Committee.

 

Alistair brings with him a wealth of consultancy and business experience. Having trained as an accountant, his early career was in senior management positions with Unilever and John Wood Group PLC. Alistair was a Director of Arthur Young (now Ernst and Young) Management Consultants and PA Consulting Group. Alistair founded Genesis Consulting and, most recently, Renaissance & Company, a strategic management consultancy working with clients across business and sport.

 

Alistair has served as Executive Chairman of the Winning Scotland Foundation and previously served as Chair of British Swimming and British Basketball, leading significant change in both sports. Alistair is currently Chairman of Edrington's Pension Trustees, responsible for management of a major private pension fund and also Chair of the trading division of John Hogg & Company. Alistair chaired the Audit and Remuneration committees of AorTech International PLC and Highland Distillers PLC, as well as the Pension Trustee Board. Alistair also served as a Fellow of the Institute of Directors and Institute of Consultants.

 

 

Stephen Parker Ph.D.  Non-Executive Chairman of Silence Therapeutics, said:

"We are delighted to welcome Alistair to the Board of Silence Therapeutics. His expertise in strategic leadership will be invaluable as we continue to expand our business and seek to deliver value to our shareholders."

 

 

Alistair William Gray, age 67, holds no shares in the Company. He holds or has held the following directorships within the last five years:

 

Current

Renaissance & Company Limited

 

Past

Winning Scotland Foundation (formerly The Scottish Institute of Sport Foundation)

British Swimming Limited

High Performance Swimming Limited

pmpgenesis Limited

Genesis Consulting Limited - dissolved

Genesis Research Limited - dissolved

Genesis Subsidiary Limited - dissolved

Genesis Red Limited - dissolved

 

Genesis Consulting Ltd, a company founded in 1992 by Alistair Gray was put into compulsory liquidation in February 2010. The associated companies were also dissolved.

 

Save as set out above, there are no further disclosures pursuant to paragraph (g) of Schedule 2 of the AIM Rules.

 

 

 

Enquiries:

 

Silence Therapeutics plc

Ali Mortazavi, Chief Executive Officer

Timothy Freeborn, Chief Financial Officer

Tel: +44 (0)20 3457 6900

 

Canaccord Genuity Limited (Nominated Adviser and Joint Broker)

Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel

Tel: +44 (0)20 7523 8350

 

 

Peel Hunt LLP (Joint Broker)

James Steel/Dr Tom Burt/Oliver Jackson

 

Tel: +44 (0)20 7418 8900

Media Enquiries:

FTI Consulting

Simon Conway/Brett Pollard/Stephanie Cuthbert

Tel: +44 (0) 20 3727 1000

 

 

 

 

Notes to Editors

 

About Silence Therapeutics plc

Our technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo.

We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics. This allows the development of therapeutics for diseases with high unmet medical need. In 2015 Silence announced interim results from a Phase 2a pancreatic cancer trial using its compound, Atu027, in combination with gemcitabine.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGMMMMMMKGKZZ
Date   Source Headline
28th Apr 20107:00 amPRNSilence (AIM: SLN) to Release Prelim Results on April 29
21st Apr 20107:00 amPRNSilence (AIM:SLN), AstraZeneca Extend RNAi Collaboration
15th Apr 20107:00 amPRNSilence Therapeutics (AIM: SLN) Appoints New CFO
13th Apr 20107:00 amPRNSilence(AIM:SLN) Integrates Assets from Intradigm Merger
30th Mar 20107:02 amPRNResearch Update
19th Mar 20103:27 pmPRNHolding(s) in Company
1st Mar 20107:00 amPRNDirectorate Change
15th Feb 20107:00 amPRNDirector/PDMR Shareholding
12th Feb 20103:28 pmPRNSenior Independent Director
12th Feb 20101:28 pmPRNNotification of Results
28th Jan 20103:00 pmPRNTotal Voting Rights
8th Jan 20101:00 pmPRNHolding(s) in Company
5th Jan 20101:35 pmPRNAcquisition and Issue of Equity
4th Jan 201012:40 pmPRNEGM Statement
17th Dec 200912:05 pmPRNStatement re Posting of Document
16th Dec 20095:03 pmRNSSchedule 1 - Silence Therapeutics plc
16th Dec 200912:00 pmRNSRestoration - Silence Therapeutics plc
16th Dec 200912:00 pmPRNAcquisition
14th Dec 200912:45 pmPRNAGM Statement
20th Nov 20097:00 amPRNNotice of AGM
15th Oct 20097:05 amPRNPatent Update
2nd Oct 20094:55 pmPRNCorrection : Half-yearly Report
30th Sep 20097:00 amPRNHalf-yearly Report
29th Sep 200910:15 amPRNTemporary Suspension
29th Sep 200910:15 amRNSSuspension - Silence Therapeutics plc
17th Sep 20097:00 amPRNNotice of Results
1st Sep 20094:40 pmRNSSecond Price Monitoring Extn
1st Sep 20094:35 pmRNSPrice Monitoring Extension
28th Aug 20094:25 pmPRNHolding(s) in Company
27th Aug 20094:40 pmRNSSecond Price Monitoring Extn
27th Aug 20094:35 pmRNSPrice Monitoring Extension
27th Aug 20097:00 amPRNRe Agreement
26th Aug 200911:30 amPRNHolding(s) in Company
14th Jul 200911:30 amPRNIssue of Equity
1st Jul 20094:40 pmRNSSecond Price Monitoring Extn
1st Jul 20094:35 pmRNSPrice Monitoring Extension
24th Jun 20097:00 amPRNAnnual Financial Report
23rd Jun 20097:00 amPRNResearch Update
19th Jun 20094:35 pmRNSPrice Monitoring Extension
3rd Jun 200912:05 pmPRNStatement re Approval for Clinical Trial
22nd May 20094:40 pmRNSSecond Price Monitoring Extn
22nd May 20094:35 pmRNSPrice Monitoring Extension
12th May 20094:40 pmRNSSecond Price Monitoring Extn
12th May 20094:35 pmRNSPrice Monitoring Extension
11th May 20094:40 pmRNSSecond Price Monitoring Extn
11th May 20094:35 pmRNSPrice Monitoring Extension
7th May 20094:40 pmRNSSecond Price Monitoring Extn
7th May 20094:35 pmRNSPrice Monitoring Extension
5th May 20094:51 pmRNSSecond Price Monitoring Extn
5th May 20094:46 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.